Clinical Trial Results:
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension
A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Group Study to Evaluate the Safety and Efficacy of Darusentan in Subjects with Resistant Hypertension Receiving Combination Therapy with Three or More
Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine or Placebo
Summary
|
|
EudraCT number |
2006-003547-23 |
Trial protocol |
FR GB DE BE DK ES CZ |
Global completion date |
19 Aug 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
05 Jan 2017
|
First version publication date |
05 Jan 2017
|
Other versions |
|
Summary report(s) |
DAR-312_Summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.